Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects

Inclusion Criteria: * Recorded Type 2 diabetes diagnosed at least 3 months before the study; At least 3 months treatment on a stable dose（≧1500mg/d）of metformin before the study * 6.5%\<HbA1c ≤10% * Clinically diagnosed simple liver steatosis * 30-75 years old * Female subjects should be postmenopausal, surgically sterile, or using contraceptives for 3 months before screening and continuing throughout the study; * BMI 20\~35 kg/m2 and with a history of stable body weight (≤10%variation for ≥3 months) * intrahepatic lipids (IHL) \>10% Exclusion Criteria: * Type 1 diabetes * Treatment within the last 3 months with Thiazolidinediones(TZDs), orlistat, insulin, any history of incretin based therapy or any other drugs associated with hepatic steatosis (including but not limited to glucocorticoids, tamoxifen, amiodarone or methotrexate) * History or current episode of pancreatitis or other disease of the pancrea; Impaired liver function, defined as plasma alanine transaminase(ALT) \>2.5 times of upper normal limit * Moderate and severe renal insufficiency defined as MDRD formula glomerular filtration rate\<60ml/min/1.73m2 * Weekly alcohol intake\>14 units for women or \>21 units for men * Any history of liver disease including metabolic or auto-immune liver diseases or viral hepatitis * History or family history of medullary thyroid cancer(MTC), or multiple endocrine neoplasia type 2(MEN-2) * Congestive heart failure(NYHA III\~IV) * Severe gastric-intestinal diseases * Pregnancy and/or intention of becoming pregnant * Known proliferative retinopathy or maculopathy requiring acute treatment as judged by the Investigator; Use of non-herbal Chinese medicine or other non-herbal local medicine with unknown/unspecified content. Herbal traditional Chinese medicine or other local herbal medicines may, at the Investigator's discretion, be continued throughout the trial at an unchanged dose